Eledon Pharmaceuticals Reports Q2 2026 Quarterly Results

What Happened
Eledon Pharmaceuticals, Inc. announced its quarterly results for the period ended June 30, 2026 by issuing a press release on August 13, 2026 and furnishing that release on Form 8-K (Item 2.02). The press release is attached to the filing as Exhibit 99.1. The report was signed by CEO David‑Alexandre C. Gros, M.D.

Key Details

• Filing date: August 13, 2026 (Form 8-K furnished under Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Disclosure: Press release attached as Exhibit 99.1 to the Form 8-K (Item 9.01 lists the exhibit).
• Authorized signatory: David‑Alexandre C. Gros, M.D., Chief Executive Officer.

Why It Matters
This Form 8-K signals that Eledon has publicly disclosed its quarterly operating and financial results. Retail investors should read the attached press release for specific figures on earnings, revenue, cash position, and any guidance or operational updates. For full audited or detailed financial statements and management discussion, watch for the company’s upcoming Form 10-Q or subsequent filings.